TAM is a ticker tracked in our intelligence system with 5 linked articles.
Penguin AI targets admin-work automation in US healthcare, citing a trillion-dollar admin spend with roughly $570B in non-outcomes-improving tasks and a serviceable market around payer-provider transactions.
TandemStride targets a $1B wedge within a $5–$10B TAM for recovery infrastructure after traumatic health events, focusing on patients leaving acute care.
Asterix Health CEO frames the healthcare workforce as a massive TAM (global ~$5T; UK ~£100B) with a current focus on primary care, signaling substantial market potential but limited detail on execution or regulatory factors.
JP Jenkins frames liquidity for private-market shareholders as their core value, citing a UK TAM in the billions and global TAM in the trillions.
Calibre’s CEO interview cites a $47B US TAM and ~$1T global TAM for preventative health, signaling a massive market opportunity but lacking product/traction specifics.
Exosystems positions its market as neuromuscular function assessment and monitoring with a global TAM over $20B, spanning diagnostics, rehabilitation, remote monitoring, and digital biomarkers for drug development.
Subscribe for real-time ticker updates and unlimited access to our intelligence platform.